News

February 22, 2021August 23, 2022

CRISPR Gene Editing Used to Build 1st Model of AML Progression

News

Blocking early inflammatory and innate immune signaling is a promising therapeutic target in acute myeloid leukemia (AML), as disruptions in these signaling pathways occur early and persist throughout the evolution ... Read more

February 18, 2021February 18, 2021

Potential Therapy May Better Prepare Older Patients Before Stem Cell Transplant

News

JSP191, an investigational therapy by Jasper Therapeutics, showed promising efficacy as a conditioning agent to prepare older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for a stem ... Read more

February 15, 2021February 15, 2021

FDA Grants Iadademstat Orphan Drug Designation

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Oryzon Genomics‘ iadademstat, an investigational oral therapy for people with acute myeloid leukemia (AML). “Receiving Orphan Drug ... Read more

February 11, 2021February 11, 2021

Eprenetapopt-Azacitidine Combo Shows Promise for AML With TP53 Mutations

News

Eprenetapopt (APR-246), Aprea Therapeutics’ lead cancer therapy candidate, was well-tolerated and showed promising clinical activity when given alongside azacitidine to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia ... Read more

February 8, 2021February 8, 2021

Xospata Conditionally Approved in China for Certain Acute Myeloid Leukemias

News

Xospata (gilteritinib) has been conditionally approved in China to treat adults who have relapsed or refractory acute myeloid leukemia (AML) with mutations in the FLT3 gene. The therapy’s conditional approval ... Read more

February 4, 2021February 4, 2021

New Combo Therapy Shows Promising Activity Against AML in Lab Studies

News

Combining two potential cancer therapies with distinct modes of action and limited clinical benefits on their own resulted in powerful anti-cancer activity in both cellular and mouse models of acute myeloid ... Read more

February 1, 2021February 1, 2021

Magrolimab Achieves Positive Results in Ongoing Phase 1b Trial

News

Gilead Sciences’ investigational therapy magrolimab was well-tolerated and effective in untreated acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, according to data from a Phase 1b trial. These results ... Read more

January 28, 2021January 28, 2021

FDA Clears Way for Clinical Trial of VOR33 Stem Cell Therapy

News

Vor Biopharma has been cleared in the U.S. to begin clinical trial testing of its investigational cell therapy, VOR33, for acute myeloid leukemia (AML). The U.S. Food and Drug Administration ... Read more

January 21, 2021January 21, 2021

Potentially Less Toxic Chemo for AML Named Orphan Drug in Europe

News

Aspacytarabine (BST-236), a possibly less toxic form of chemotherapy being developed by Biosight for people with acute myeloid leukemia (AML), has been designated an orphan medicinal product by the European Medicines ... Read more

January 18, 2021January 18, 2021

Iomab-B Shows Promise as Transplant Conditioning Regimen

News

Iomab-B shows promise as a conditioning regimen for bone marrow transplant in patients older than 55 with active relapsed or refractory acute myeloid leukemia (AML), according to early data from ... Read more